Gabapentin
Product Images NDC 71093-163

Product Visual Gallery

This gallery contains 9 technical images submitted to the FDA as part of the official labeling for Gabapentin (NDC 71093-163). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Aci Healthcare Usa, Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Image Description (Gabapentincapsules 01)

A formula illustrating the calculation for creatinine clearance (CLCr), which involves age in years, weight in kilograms, serum creatinine in mg/dL, and a factor of 0.85 for female patients.*

FDA Label Image

Chemical Structure (Gabapentincapsules 02)

Chemical structure of Gabapentin showing a cyclohexane ring with amino and carboxyl groups attached, representing its molecular framework.*

FDA Label Image

Figure 1 (Gabapentincapsules 03)

A line graph depicting mean pain score over an 8-week period for Gabapentin 3600 mg/day versus placebo. The x-axis shows weeks, including a 4-week dose titration period and a 4-week fixed dose period. The y-axis shows mean pain score from 0 to 10, with Gabapentin scores decreasing over time and placebo scores remaining relatively stable.*

FDA Label Image

Figure 2 (Gabapentincapsules 04)

A line graph showing mean pain scores over 7 weeks for Gabapentin at 1800 mg/day, Gabapentin at 2400 mg/day, and placebo. The x-axis represents weeks from baseline to week 7, and the y-axis shows mean pain scores. The graph indicates a 3-week dose titration period followed by a 4-week fixed dose period, with pain scores decreasing more for both Gabapentin doses compared to placebo.*

FDA Label Image

Figure 3 (Gabapentincapsules 05)

A bar chart titled "Proportion of Responders (patients with ≥ 50% reduction in pain score) at Endpoint: Controlled PHN Studies" showing results from two studies. Study 1 compares placebo (PBO) with Gabapentin 3600 mg, indicating a higher response for Gabapentin. Study 2 compares placebo with Gabapentin 1800 mg and 2400 mg, both showing increased responder proportions relative to placebo. Statistical significance is noted with p-values less than 0.01 and 0.001.*

FDA Label Image

Figure 4 (Gabapentincapsules 06)

A scatter plot comparing differences (%) versus daily dose (mg) for Gabapentin in three studies labeled a, b, and c. The graph shows individual data points for doses 600 mg, 900 mg, 1200 mg, and 1800 mg with percentage differences rising as dose increases.*

FDA Label Image

100 mg (Gabapentincapsules 100mg 100s 07)

Gabapentin Capsules, USP 100 mg label from ACI Healthcare USA, Inc. The label shows the active ingredient strength as 100 mg per capsule and a package size of 100 capsules. It includes storage instructions, manufacturer information (Zhejiang Yongtai Pharmaceutical Co., Ltd., China), a QR code link for medication guides, and barcode details.*

FDA Label Image

300 mg (Gabapentincapsules 300mg 100s 08)

Label for Gabapentin Capsules, USP 300 mg by ACI Healthcare USA, Inc. The label indicates the packaging contains 100 capsules and includes storage instructions, manufacturer details (Zhejiang Yongtai Pharmaceutical Co., Ltd.), and directions to a medication guide online or via QR code. The label features green and pink color blocks with dosage and use information.*

FDA Label Image

400 mg (Gabapentincapsules 400mg 100s 09)

Label for Gabapentin Capsules USP 400 mg by ACI Healthcare USA, Inc. The label indicates each capsule contains 400 mg of gabapentin, with a package size of 100 capsules. Storage instructions and manufacturer details are included, along with a barcode and QR code for medication guide access.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.